This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pfizer, Flynn Pharma can appeal fines over epilepsy-drug pricing behaviors: UK CAT

( March 5, 2025, 17:01 GMT | Official Statement) -- MLex Summary: Pfizer and Flynn Pharma can appeal fines imposed by the Competition Appeal Tribunal over epilepsy-drug pricing behaviors, the CAT has ruled. The CAT's ruling to fine the companies, through a remade decision, came after the drugmakers challenged multimillion-pound sanctions imposed on them by the Competition and Markets Authority. An original set of fines by the CMA had earlier been quashed on appeal. Ruling attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections